登录新浪财经APP 搜索【信披】查看更多考评等级 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。但公司已就业绩预告 有关重大事项与年度审计会计师事务所进行了预沟通，公司与会计师事务所在本报告期的业绩预告方面 不存在重大分歧。 三、业绩变动主要原因说明 1、优化业务结构布局，短期业绩受影响 2025年公司以"增加销售毛利、保障资产安全、改善融资渠道、优化资金回报"为经营管理指导思想，围 绕现金流为核心，以效益最大化为目标，组织开展各项经营活动。在推进业务拓展的同时，公司聚焦资 产优化与资源整合，着力提升可持续发展能力。公司对长期亏损、不符合核心战略的子公司或业务板块 进行综合评估，通过股权转让、资产出售、清算等方式剥离不良资产。公司已对部分子公司采取停止业 务措施，受相关清算程序尚未完成的影响，预计影响本报告期净利润亏损约11,000万元-15,000万元（最 终金额经会计师事务所审计后确定）。上述举措虽在短期内影响了公司整体经营规模与利润贡献，但有 效优化了资产质量与现金流，为促进公司长期健康稳步发展奠定坚实基础。 本公司及董事局全体成员保证信息披露的内容 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经华熙生物科技股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现归属 于母公司所有者的净利润人民币27,000.00万元到32,000.00万元，与上年同期（法定披露数据）相比，将 增加9,573.26万元到14,573.26万元，同比增加54.93%到83.63%。 （2）预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润16,700.00万元到21,700.00 万元，与上年同期（法定披露数据）相比，将增加5,972.80万元到10,972.80万元，同比增加55.68%到 102.29%。 二、上年同期业绩情况和财务状况 （一）利润总额：21,339.29万元。归属于母公司所有者的净利润：17,426.74万元。归属于母公司所有者 的扣除非经常性损益的净利润：10,727.20万元。 组织层面，公司整合职能重叠部门，优化 ...

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -85 million yuan and -66 million yuan [2] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -84 million yuan and -65 million yuan [3] - The financial data in this performance forecast has not been audited by a registered accountant [4] Group 2 - In the same period last year, the total profit was -54.2183 million yuan, with a net profit attributable to shareholders of the parent company at -54.4163 million yuan, and a net profit after deducting non-recurring gains and losses at -71.7486 million yuan [5] - The earnings per share for the previous year was -0.78 yuan per share [6] Group 3 - The main reasons for the performance changes include an increase in revenue from the main business due to the continuous enrichment of the product line and the development of new business [6] - The company has increased its R&D investment in areas such as RNA drugs, antibody drugs, gene and cell therapy, organoids, and synthetic biology to strengthen its technological advantages [6] - The company has expanded its marketing team and enhanced brand marketing efforts, leading to an increase in sales expenses [6] - A reduction in government subsidies compared to the previous year has been noted, impacting other income [7]

荣昌生物制药（烟台）股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 证券代码：688331 证券简称：荣昌生物 公告编号：2026-006 港股代码：09995 港股简称：榮昌生物 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经荣昌生物制药（烟台）股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年度营 业收入约325,000万元，与上年同期相比，将增加收入约153,314万元，同比增加约89%。 （2）公司预计2025年度实现归属于母公司所有者的净利润约71,600万元，与上年同期相比，实现扭亏 为盈。 （3）公司预计2025年度归属于母公司所有者扣除非经常性损益后的净利润约7,850万元，与上年同期相 比，实现扭亏为盈。 （三）本期业绩预告相关的财务数据未经注册会计师预审计。 二、上年同期业绩情况 2024年度营业收入171,686.17万元。 2024年度归属于母公司所有者扣除非经常性损益后的净亏损1 ...

Core Viewpoint - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. forecasts a revenue increase for 2025, while also projecting a higher net loss compared to the previous year, primarily due to the absence of investment gains from subsidiary disposals in 2024 [2][5]. Group 1: Performance Forecast - The company expects to achieve an operating revenue of approximately CNY 140 million to CNY 145 million in 2025, representing a year-on-year increase of 8.13% to 11.99% [2][5]. - The projected net loss attributable to shareholders is estimated to be between CNY 255 million and CNY 290 million, an increase in loss of approximately CNY 53.62 million to CNY 88.62 million compared to 2024 [2][5]. - The net loss excluding non-recurring gains and losses is expected to be between CNY 288 million and CNY 323 million, a reduction in loss of approximately CNY 4.31 million to CNY 39.31 million, mainly due to revenue growth and reduced expenses [2][5]. Group 2: Revenue Sources - Revenue is primarily derived from the sales of the innovative anti-HIV drug Aikening (generic name: Aibowei Tai), the agency product Viread (Tenofovir), and the newly approved far-infrared therapeutic patch (Xiaoyan Yipai) [2][5]. - The sales of Aikening are focused on the inpatient market, with continued growth in outpatient revenue, supported by its reputation as a preferred medication for hospitalized patients [5][6]. Group 3: R&D and Commercialization Progress - The company is focusing on the research and development of small nucleic acid drugs and has submitted IND applications for several candidates, including FB7013 and FB7011, which are in various stages of clinical development [7][8]. - The company has completed nationwide sales registration for the agency product Viread and has initiated commercial promotion for the far-infrared therapeutic patch [6][8]. - R&D expenses are projected to be between CNY 138 million and CNY 145 million, reflecting a year-on-year increase of 0.58% to 5.68%, as the company emphasizes early-stage development of new drugs [5][7].

证券代码：688166 证券简称：博瑞医药（维权） 公告编号：2026-003 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润4,130万元到6,190万元，与 上年同期（法定披露数据）相比将同比减少67.28%到78.17%。 2、预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润430万元到2,490万元，与上 年同期（法定披露数据）相比将同比减少86.21%到97.62%。 博瑞生物医药（苏州）股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 3、BGM1812注射液：BGM1812是公司优化设计的新型长效Amylin类似物，具有良好的分子活性和药 学稳定性。Amylin（胰淀素）作为一种由37个氨基酸组成的饱腹感多肽激素，由胰腺β细胞与胰岛素协 同释放入血。它通过激活大脑饱腹感通路抑制食欲，同时延缓胃排空、抑制胰高血糖素分泌，具有多 ...

Core Viewpoint - The company, Changchun High-tech (SZ000661), has issued a shocking earnings forecast for 2025, predicting a significant decline in net profit compared to the previous year, primarily due to increased R&D expenses, adjustments in sales strategies following the inclusion of long-acting growth hormone products in the national medical insurance catalog, and losses from its subsidiary [2][3]. Group 1: Earnings Forecast - For 2025, the company expects a net profit attributable to shareholders between 150 million to 220 million yuan, a drastic decrease of 91.48% to 94.19% from 2.583 billion yuan in 2024 [2]. - The forecasted net profit excluding non-recurring items for 2025 is estimated to be between 437 million to 507 million yuan, down 82.09% to 84.56% from 2.830 billion yuan in the previous year [2]. Group 2: Reasons for Profit Decline - The decline in profit is attributed to multiple factors, including increased R&D expenses as several products enter clinical stages and higher sales expenses for promoting new products [3]. - The company adjusted its sales strategies and pricing for long-acting growth hormone products after they were included in the national medical insurance catalog, which negatively impacted revenue and profit [3]. - Losses from the subsidiary, Changchun Baike Biotechnology Co., further contributed to the overall decline in performance [3]. Group 3: Market Position and Challenges - The company holds a 100% market share in the pegylated recombinant human growth hormone injection and a 68.4% market share in short-acting growth hormone products, indicating a strong competitive position [4]. - However, starting in 2024, the company began experiencing a downward trend in performance, with revenues and net profits decreasing by 7.55% and 43.01%, respectively, in 2024 [5]. - The introduction of price reductions for growth hormones in 2025 is expected to exert additional pressure on revenue growth [5]. Group 4: Strategic Initiatives - The company is increasing its R&D investment, which rose by 23% to 1.733 billion yuan in the first three quarters of 2025, representing 17.68% of total revenue [5]. - A recent business development transaction with Yarrow Bioscience, Inc. is expected to yield significant future payments, although these revenues will not be recognized in the 2025 financial statements [6]. - The company is also focusing on expanding its overseas market presence and has submitted an application for listing on the Hong Kong Stock Exchange to support this initiative [6].

1月30日，新诺威（300765）及其间接控股股东石药集团相继公告，宣布与全球生物制药巨头阿斯利康 (AstraZeneca)签署战略研发合作与授权协议，将在创新多肽分子发现和长效递送产品的开发领域开展全 面战略合作。 合作总金额 最高可达185亿美元 根据石药集团公告，在中国以外，阿斯利康将获得该集团"每月一次注射用体重管理产品组合"的全球独 家权利——包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临床)，以及 三个处于临床前阶段、具备不同作用机制的研发项目。 根据石药集团公告，阿斯利康将向石药集团支付12亿美元预付款。此外，石药集团有权获得最高35亿美 元的潜在研发里程碑付款和最高138亿美元的潜在销售里程碑付款，以及基于相关授权产品年净销售额 的最高达双位数比例的销售提成。若所有里程碑均达成，该合作总金额最高可达185亿美元。 针对此次合作，添翼数字经济智库高级研究员吴婉莹对记者表示，此次石药集团与阿斯利康创纪录的战 略合作，标志着其"创新+国际化"战略取得里程碑式突破，不仅以巨额合作金额强力验证了其AI药物发 现与缓释给药等前沿技术平台的全球竞争力，为正处于传统 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《国联民生证券承销保荐有限公司关于杭州安旭生物科技股份有限公司部分募集资金投资项目延 期的核查意见》 《安旭生物2025年年度业绩预告》 《安旭生物关于部分募集资金投资项目延期的公告》 截至2026年1月30日收盘，安旭生物（688075）报收于40.24元，较前一交易日下跌0.57%，最新总市值 为51.14亿元。该股当日开盘40.29元，最高40.71元，最低39.5元，成交额达3109万元，换手率为 0.61%。 近日，杭州安旭生物科技股份有限公司披露《2025年年度业绩预告》。公告显示，公司预计2025年年度 实现归属于母公司所有者的净利润7,100.00万元到8,500.00万元，同比减少55.80%到63.08%；扣除非经 常性损益的净利润1,300万元到1,560万元，同比减少58.84%到65.70%。业绩下滑主要因美国加征关税导 致订单减少、营业成本上升，叠加汇率波动、汇兑损失、利息收入降低及资产折旧摊销等因素所致。同 时公司加大新技术平台投入及海外市场布局，费用增加 ...

证券日报网讯1月30日，前沿生物发布公告称，公司预计2025年度实现营业收入约14，000.00万元到 14，500.00万元，同比增加8.13%到11.99%，归属于上市公司股东的净利润亏损约25，500.00万元到亏 损29，000.00万元，增加亏损约5，361.74万元到8，861.74万元。 ...